(Q36349717)

13 August 2017

1 reference

title

Toxicity of infliximab in the course of treatment of Crohn's disease (English)

1 reference

13 August 2017

0 references

Jason M Bratcher

1

1 reference

13 August 2017

Burton I Korelitz

series ordinal

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

Expert Opinion on Drug Safety

13 August 2017

published in

1 reference

13 August 2017

volume

5

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

9-16

1 reference

An evolutionary and functional approach to the TNF receptor/ligand family

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Tumor necrosis factor: a pleiotropic cytokine and therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Detection of tumour necrosis factor alpha in sarcoidosis and tuberculosis granulomas using in situ hybridisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Inhibition of Thl responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Cytokine patterns in the pathogenesis of human leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Limitations and strengths of spontaneous reports data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

TNF-alpha controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Pulmonary granulomas after tumour necrosis factor alpha antagonist therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

The molecular action of tumor necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Infliximab and reactivation of cerebral toxoplasmosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Peptostreptococcal pericarditis complicating anti-tumour necrosis factor alpha treatment in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Mortality associated with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Diffuse alveolar hemorrhage after infliximab treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Kaposi's sarcoma associated with tumour necrosis factor alpha neutralising therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Autoantibodies in human ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Soluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies, and other autoantibodies in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Adverse reactions to biological modifiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Infliximab-induced lupus in Crohn's disease: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

A lupus-like syndrome associated with infliximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Case reports of heart failure after therapy with a tumor necrosis factor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Infliximab-associated retrobulbar optic neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Retrobulbar optic neuritis associated with infliximab in a patient with Crohn disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

Invasive Pulmonary Aspergillosis Associated with Infliximab Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.9

21 January 2018

Identifiers

DOI

10.1517/14740338.5.1.9

1 reference

13 August 2017

1 reference